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Aims: To examine the levels of endothelin system components in granulosa lutein cells (GLCs) of womenwith
PCOS and compare them to normally ovulating women undergoing In Vitro Fertilization (IVF).
Polycystic ovary syndrome (PCOS) is one of the most common endocrine-metabolic disorders in women of
reproductive age. Endothelins are locally produced by endothelial and granulosa cells of the preovulatory fol-
licle. Abnormal expression or production of endothelins may be a contributing factor in PCOS pathogenesis.
Main methods: Follicular aspirates containing GLCs were obtained from PCOS and normally ovulating patients
undergoing oocyte retrieval during the IVF cycle. RNA was extracted and endothelin system components
were quantiﬁed using real-time PCR. GLCs were cultured in basal media for 7 days, and then challenged
with various luteinizing agents (luteinizing hormone, hCG, or forskolin) for 24 h.
Key ﬁndings: In GLCs from women with PCOS, Endothelin-1 mRNA expression was elevated (2.2-fold) as
compared with normally ovulating women, whereas endothelin-2 mRNA was reduced (1.8-fold). ET recep-
tors and endothelin-converting enzyme showed the same expression levels in the two groups. In vitro
modeling showed that although the steroidogenic response was preserved in GLC, endothelin expression
levels were not exhibited in vitro in their original pattern.
Signiﬁcance: Dysregulation of ovarian endothelin expression may induce a pathologic ovulation pattern char-
acteristic of PCOS.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Polycystic ovary syndrome (PCOS) is a clinical diagnosis charac-
terized by the presence of two or more of the following features:
chronic oligo-ovulation or anovulation, clinical or biochemical hyper-
androgenism, and polycystic ovaries appearing on an ultrasound scan
(Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop
Group, 2004). PCOS affects 5 to 10% of women of childbearing age,
and it is the most common cause of anovulatory infertility in devel-
oped countries (Asuncion et al., 2000). It has been proposed that
PCOS results from abnormal regulation of steroidogenesis and specif-
ically from androgen secretion by the ovary (Wickenheisser et al.,
2000). Provocative tests using GnRH agonists have shown that the
hyperandrogenism usually has an ovarian source (Rosenﬁeld et al.,
2000). PCOS is also associated with signiﬁcant metabolic derange-
ments such as hyperinsulinemia and insulin resistance (Legro et al.,
2004). These metabolic derangements may predispose the patient
to a range of diseases with attendant morbidity and mortality risks.ynecology, Hadassah-Hebrew
035, Jerusalem 91240, Israel.
-NC-ND license.The prevalence of themetabolic syndrome (obesity, an abnormal lipo-
protein proﬁle, high blood pressure, and increased fasting glucose) is
two to three times as high among women with PCOS compared with
normal women matched for age and body-mass index (Apridonidze
et al., 2005). Although ovulation induction treatments are successful
in getting these women to ovulate, data from women with PCOS
undergoing IVF treatment show that their oocytes are often of poor
quality, leading to lower fertilization, cleavage, and implantation
rates, and these women suffer from a higher miscarriage rate (Qiao
and Feng, 2011). The pathophysiological characteristics of the poly-
cystic ovary syndrome are not fully understood but are known to
involve complex interactions among gonadotrophic peptides, ovarian
cells and hormones, androgens, and insulin.
Endothelins (ETs) are a family of peptides involved in many phys-
iological processes (Khimji and Rockey, 2010). Their involvement in
PCOS was suggested by the observation that obese and non-obese
womenwith PCOS have higher levels of circulating endothelin-1 com-
pared with controls (Diamanti-Kandarakis et al., 2001). Endothelial
cells produce endothelins, but endothelin-1 is also expressed in
ovarian cells and the peptide is present in the follicular ﬂuid of normal
women (Magini et al., 1996; Mancina et al., 1997; Iwai et al., 1993).
Moreover, the concentration of endothelin-1 is negatively correlated
Table 1
Clinical characteristics and cycle outcome in normal ovulatory and PCOS patients.
PCOS
(n=14)
Normal ovulatory patients
(n=17)
P
Age (years) 27.3±4 28.9±5 NS
BMI (kg/m2) 28±5.5 24±4 NS
FSH (mU/L) 4.9±1.5 5.7±1.5 NS
LH (mU/L) 6.0±3.6 3.5±2.2 b0.05
Total testosterone (nmol/L) 2.8±1.2 2.3±0.6 NS
E2 level during ovulation (pmol/L) 9591±3659 8533±3253 NS
No. of oocytes 20.6±9.6 16.6±5.6 NS
No. of embryos 13.1±6.3 9.3±3.3 NS
Data presented as mean±SD.
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peptide was recently shown to have an important ovarian function:
produced by the granulosa cells around the time of ovulation,
endothelin-2 affects follicular rupture and corpus luteum formation
(Ko et al., 2006; Klipper et al., 2010). The present study was under-
taken to investigate whether women with PCOS have altered levels
of the endothelin system constituents in their granulosa lutein cells
(GLCs). We determined the mRNA levels of endothelin-1, endothelin-2,
their converting enzyme, ECE-1, and the two receptor subtypes, ETA
and ETB, in freshly isolated GLCs from women with PCOS and compared
them to GLCs from age-matched normally ovulating women. The
patients underwent ovulation induction and ovum pick-up through an
in-vitro fertilization cycle. We also examined the effects of luteotrophic
agents on endothelin production and the steroidogenic response of
cultured GLCs derived from PCOS and normally ovulating women.
Materials and methods
Subjects
Women with PCOS and normally ovulating women (12 and 14,
respectively) were enrolled in this study. Diagnosis of PCOS was made
according to the Rotterdam revised criteria (2004). The Hadassah
HebrewUniversityMedical Center Institutional Review Board approved
this study. All subjects gave written informed consent to participate
in the study.
Treatment protocol
All patients were subjected to the long suppression protocol
(Fleming et al., 1988). In brief, gonadotropin-releasing hormone ago-
nist (3.75 mg Decapeptil; Ferring Pharmaceutical, Malmo, Sweden)
was utilized for 14 days until ovarian depressionwas complete. There-
after, recombinant FSH (75 IU Gonal F; Seono, Israel) was adminis-
tered, at a dose of 2 ampoules a day and subsequently adjusted
according to the individual's response. When >3 follicles reached
>18 mm in diameter, 5000 IU of human chorionic gonadotropin
(hCG) (Organon, Oss, Holland) was injected into the patient to induce
ovulation. Transvaginal oocyte retrieval was performed using ultra-
sound probe guidance 36 h after hCG. All accessible follicles were
harvested and oocytes were removed from follicular aspirates for
further fertilization and embryo transfer. The residual follicular ﬂuid
aspirates containing GLCs were collected for further investigation.
Experiment protocol
Follicular ﬂuids containing GLCs and erythrocytes were cen-
trifuged. Follicular ﬂuid was decanted, and erythrocytes were lysed
using ACK solution (0.15 M NH4Cl, 1.0 mM KHCO3, and 0.1 nM
EDTA) for 15 min at 37 °C. The cells were then washed 3 times with
10 ml of PBS (300×g, 4 min). Finally, cells were counted in a hemocy-
tometer. A fraction of the freshly isolated cells were taken for RNA
extraction using Tri-Fast reagent (Peqlab. Erlangen, Germany). The
remaining cells were placed in 6-well dishes (~1.5×106 cells per
well). GCs were cultured in a DMEM-F12 1:1 (v/v) nutrient mixture
containing 10% fetal calf serum (FCS), 1% L-glutamine, and 1% penicil-
lin streptomycin (Biological Industries, Kibbutz Beit Haemek, Israel).
Cultures were maintained in humidiﬁed 95% air–5% CO2 at 37 °C.
GLCs from six normally ovulating patients and GLCs from 7 women
with PCOS were cultured in media containing 10% FCS. Following
7 days culture, cells were washed and challenged with either hCG
(10 units/ml), 100 nM LH, 10 μM forskolin (FRS), or left without
treatment. Twenty-four hours later, media were collected from each
well for further progesterone analysis.
RNA isolation and real-time PCR
Total RNAwas isolated from freshly isolated and cultured cells using
Tri-Fast reagent (Peqlab Biotechnologie GmbH, Erlangen, Germany)
according to the manufacturer's instructions. Real-time PCRs wereperformed using the Mx3000P quantitative PCR system (Stratagene,
Garden Grove, CA), with the SYBR Green I PCR kit with ROX passive ref-
erence (Eurogentec, Seraing, Belgium) as previously described (Klipper
et al., 2009). Brieﬂy, each real-time reaction (18 μl) contained the SYBR
Green master mix that comprised the ROX 6-carboxy-X-rhodamine
passive reference, 1.5 mM deoxynucleotide triphosphates, including
deoxyuridine 5-triphosphate, 5 mM MgCl2, uracil N-glycosylase, and
Amplitaq HotGoldStar DNA polymerase, 0.54 μl of a 1:10,000 dilution
of SYBR Green stock solution, 10 nM of each primer, and cDNA. The
glyceraldehyde 3-phosphate dehydrogenase (GPDH) gene was used
as the housekeeping gene. Dissociation curve analysis was performed
after each real-time experiment to conﬁrm the presence of only one
product and the absence of the formation of primer dimers. The thresh-
old cycle number (Ct) for each tested gene X was used to quantify
the relative abundance of the gene; arbitrary units were calculated as
2−ΔCt=2−(Ct target gene×−Ct housekeeping gene). Primers that
were used were as follows: G3PDH, forward 5′-GGGAAACTGTG-
GCGTGATG-3′ and reverse 5′ CCGTTCAGCTCAGGGATGAC-3′; ECE-1,
forward 5′-GGAGAACATCGCCGACAAC-3′ and reverse 5′-TGCAAAGC-
CCAGGAAGAAG-3′; ET-1, forward 5′-CTGCCACCTGGACATCATTTG-3′
and reverse 5′-TCTCACGGTCTGTTGCCTTTG-3′; ET-2, forward, 5′-GC-
CAGCGTCCTCATCTCAT-3′, reverse, 5′-GCCGTAAGGAGCTGTCTGTTC-3′;
ETA, forward 5′-GCTTCCTGGTTACCACTCATCAA-3′ and reverse 5′-GT-
CTGCTGTGGGCAATAGTTG-3′.
ETB, forward, 5′-GAGCGTGGATACTGGCGAAGA-3′, reverse, 5′-CC-
GCTCCGCAGTTTCAGAG-3′.
StAR, forward, 5′-TGGCATGGACACAGACTTCG-3′, reverse, 5′-AGG-
ACCTGGTTGATGATGCTCT-3′.
Hormonal assay
Progesterone concentrations were measured in the culture media
by commercially available RIA Kits (Coat-A-Count Progesterone RIA,
DPC, Los Angeles, CA, USA).
Statistical analysis
Data are not normally distributed; the non-parametric Mann
Whitney U test was used to analyze data using SPSS software Version
14 for Windows. A value of Pb0.05 was considered statistically signif-
icant. Results are presented as means±sem.
Results
Clinical data
Age, body mass index (BMI), levels of gonadotrophins (FSH and
LH) on day 3 of the cycle, total testosterone, estradiol (E2) on the
day of hCG injection, the number of oocytes collected, and the num-
ber of embryos developed are presented in Table 1. As expected, LH
levels are signiﬁcantly higher in women with PCOS; this is in accor-
dance with the syndrome's characteristics (Tropeano et al., 1996).
Although the BMI tended to be higher in women with PCOS, it did
not reach statistical signiﬁcance. Estradiol levels at the day of hCG in-
jection and the number of ovum retrieved were not different between
P= 0.046
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Fig. 1. mRNA levels of endothelin-1 and endothelin-2 in human GLCs from PCOS and normally ovulating patients (14 and 17, respectively). RNA extraction, cDNA synthesis, and
real-time PCR were as described in the Materials and methods section. Results are presented as means±sem.
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before the ovum pick up.
Expression of the endothelin system in GLCs from PCOS and normally
ovulating women
We characterized the expression proﬁle of the endothelin system
in freshly collected GLCs. Quantitative RT–PCR analysis revealed that
transcripts of endothelin-1, endothelin-2, ECE-1, and ET receptors A
and B were present (Figs. 1 and 2) in both groups. The results show
that although both endothelin-1 and endothelin-2 are expressed in
human GLCs, endothelin-2 is the predominant endothelin isoform in
human GLC regardless of the group of women. More speciﬁcally, it
was expressed at least 10-fold higher than endothelin-1 in the GLCs
from normal women and from women with PCOS. Interestingly, we
observed here that the levels of endothelin-1 in the GLCs from
ovulating follicles were signiﬁcantly elevated in those from women
with PCOS as compared with those from normally ovulating women
(a 2.2-fold difference). Endothelin-2 mRNA expression, on the other
hand, was signiﬁcantly lower in GLCs from PCOS than in normally
ovulating women (Fig. 1).
ECE-1 mRNA is highly expressed in the GLCs from both groups
(Fig. 2).
Similarly, both endothelin receptor subtypes (ETA and ETB) were
readily detected in freshly isolated GLCs from the two groups. However,
the ETA receptor mRNA was 5-fold higher than ETB in GLCs. Unlike
endothelin mRNA expression, which differed signiﬁcantly between
the groups, StAR transcripts were the same in both groups (Fig. 3).
Effects of gonadotropin withdrawal on cultured human GLCs
Cells were cultured in basal media for 7 days to examine the
effects of gonadotropin deprivation in each group of patients. DataPCOSNormal 
Ovulatory
ECE-1
0.00
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Fig. 2. mRNA levels of ECE-1 and ET‐R (receptors) in human GLC from PCOS and normally o
time PCR were as described in the Materials and methods. Results are presented as meansdepicted in Fig. 4 show the precipitous decline in StAR mRNA after
7 days of culture without gonadotropins, as compared with cells
obtained soon after (36 h) hCG treatment. The decline in steroidogen-
esis was similar in both groups. However, the mRNA from the two
endothelins exhibited an opposite pattern after 7 days of culture.
Endothelin-1 expression was markedly and signiﬁcantly elevated;
this rise was observed in cells from both groups cultured in basal
media (Fig. 5). Interestingly, endothelin-2 levels declined in GLCs
from normally ovulating women (3–4-fold decrease, Pb0.05) but
did not change signiﬁcantly in the PCOS group (Fig. 5).Effect of luteotropic agents on steroidogenesis and endothelin expression
in human GLCs in vitro
In order to examine the GLC response to luteotropic signals after
7 days of culture under basal conditions, cells from each group of
patients were challenged with various luteinizing agents (luteinizing
hormone, hCG, or FRS) for 24 h, as detailed in the Materials and
methods (Figs. 6 and 7). All agents signiﬁcantly enhanced progester-
one production, with FRS being the most potent inducer (6–7-fold,
Fig. 6). Induction of progesterone production and endothelin ex-
pression by GLCs was not statistically different between normally
ovulating and PCOS women.
Luteotrophic agents reduced themRNAexpression of the endothelin-
1 gene in the GLCs of normally ovulating and PCOS women. Twenty-
four hours treatment with FRS nearly eliminated endothelin-1 expres-
sion (a 10- and 20-fold decrease, respectively, for normal ovulatory
and PCOS women, Fig. 7A). Endothelin-2 expression also tended to
decrease in the presence of luteinizing agents (Fig. 7B). However,
the magnitude was smaller than that observed for endothelin-1, with
maximal inhibition not higher than twofold as compared with control
media. Moreover, in cells from PCOS women, only FRS could signiﬁ-
cantly reduce Endothelin-2.ET-R 
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Fig. 3. mRNA levels of StAR in human GLC from PCOS and normally ovulating patients
(14 and 17, respectively). RNA extraction, cDNA synthesis, and real-time PCR were as
described in the Materials and methods. Results are presented as means±sem.
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Fig. 5. mRNA levels of endothelin-1 (A) and endothelin-2 (B) in freshly collected GLCs
(day 0) and after 7 days in culture (day 7). RNA extraction, cDNA synthesis, and real-time
PCR were as described in the Materials and methods. n.s — non signiﬁcant statistically.
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The ovulatory process, culminating in the expulsion of an MI
oocyte and the formation of an active corpus luteum, is a central
event in the reproductive cycle. PCOS involves abnormal ovulation,
steroid production, and corpus luteum function. Although modern
fertility treatments assist PCOS women in ovulating and achieving
pregnancy, they occur at a lower frequency than in normally ovulating
women, and other implantation-related abnormalities, such as high
miscarriage rates, persist in PCOS (Weghofer et al., 2007). Impaired
oocyte maturation and embryonic developmental competence in
PCOS women is possibly linked with abnormal endocrine/paracrine
factors, metabolic dysfunction, and alterations in the intrafollicular
microenvironment during folliculogenesis and follicle maturation
(Dumesic et al., 2008; Dumesic and Abbott, 2008; Franks et al., 2002;
Wood et al., 2007).
This disorder is considered not only a reproductive endocrinopathy
but also a metabolic disorder associated with long-term health risks
(Wild, 2002), including diabetes mellitus (Diamanti-Kandarakis, 2006;
Talbott et al., 2007) and coronary artery disease (Cibula et al., 2000;
Talbott et al., 2001). One of the early signs of its vascular damage is
an endothelial injury (Pignoli et al., 1986). Endothelin-1 is expressed
as a result of endothelial cell damage and is regulated by factors asso-
ciated with platelet aggregation, macrophage inﬁltration, and the for-
mation of atherosclerotic lesions (Maemura et al., 1992). Although
serum endothelin-1 levels are signiﬁcantly elevated in women with
PCOS (Diamanti-Kandarakis et al., 2001), it is not known whether
endothelin-1 elevation is one of the etiologic factors underlying the
syndrome or whether it results from its metabolic derangements.
Our study conﬁrms previous ﬁndings showing the presence of
individual endothelin components in the human and primate ovary
(Apa et al., 1998; Choi et al., 2011; Haq et al., 1996; Karam et al.,
1999; Korth et al., 1999; Mancina et al., 1997). In the current study,
we compared the expression proﬁle of the endothelin system and0
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Fig. 4.mRNA levels of StAR in freshly collected GLCs (day 0) and after 7 days in culture
(day 7). RNA extraction, cDNA synthesis, and real-time PCR were as described in the
Materials and methods.its effect on GLC functions in women with the polycystic ovary syn-
drome and age-matched normally ovulating women undergoing
follicular aspiration during an IVF cycle. Our ﬁndings also support
previous reports showing that endothelins are present in follicular
ﬂuid (Gentili et al., 2001; Haq et al., 1996). Their levels in the follicu-
lar ﬂuid are signiﬁcantly higher than their levels in the serum (Choi
et al., 2011), suggesting that endothelins are produced endogenously.
However, their levels from hyper-stimulated IVF patients are too
scattered and thus endothelins are not suitable as a biomarker for
the ovulation process (Plonowski et al., 1999). Therefore, we evaluat-
ed their expression levels in the GLCs. In comparing endothelin
system expression in GLCs from normal vs. PCOS women, we found
altered endothelin gene expression in patients suffering from this
syndrome. These differences might be related to the mechanism
underlying this syndrome.
Higher levels of endothelin-1, which were observed in the PCOS
group, may act as a negative regulator of granulosa and luteal cells.
In vitro cultures, using human granulosa or luteal cells, have shown
that endothelin-1 inﬂuences ovarian steroidogenesis and inhibits0
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Fig. 6. Progesterone production by human GLCs from PCOS and normally ovulating
patients. After 7 days of culture, cells were further incubated for 24 h in the presence
of either 100 nM LH, hCG (10 units/ml), 10 μM forskolin (FRS), or media alone. At the
end of the incubation period, the media were collected and kept frozen until assayed
for progesterone using EIA. * denotes signiﬁcant statistical difference (Pb0.05) from
controls.
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Fig. 7.mRNA expression of endothelin-1 (A) and endothelin-2 (B) in human GLC from
PCOS and normally ovulating patients. After 7 days of culture, cells were further incu-
bated for 24 h in the presence of either 100 nM LH, hCG (10 units/ml), 10 μM forskolin
(FRS), or media alone. At the end of the incubation period, the media were decanted
and RNA was extracted from the cells. RNA extraction, cDNA synthesis, and real-time
PCR were as described in the Materials and methods. * denotes signiﬁcant statistical
difference (Pb0.05) from controls.
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terone synthesis (Apa et al., 1998; Denkova et al., 2000; Kamada
et al., 1995; Tedeschi et al., 1992). Moreover, it has been suggested
that endothelin-1 plays a role in follicular development, perhaps
by inhibiting premature ovulation and luteinization (Flores, 2000;
Shimizu et al., 2007). Its elevated levels in the follicles of PCOS
women may contribute to the abnormal ovulation process, which is
the hallmark of the disease.
Notably, in contrast to endothelin-1, we found here lower levels of
endothelin-2 mRNA in GLCs derived from women with PCOS. In fact,
the GLCs from the PCOS group had a distinct proﬁle of endothelin-2
expression. Its levels, which were lower in freshly isolated cells, did
not decline further after 7 days in culture medium deprived of gonad-
otrophins. Like their normal counterparts, an abnormally higher
endothelin-2 mRNA expression level may explain why there was no
signiﬁcant reduction by the luteotropic agents, suggesting aberrant
endothelin-2 expression in GLCs from PCOS women. In rat and
mouse models, endothelin-2 was transiently expressed in GLCs im-
mediately before gonadotropin-induced ovulation (Al-Alem et al.,
2007; Ko et al., 2006; Palanisamy et al., 2006). Blocking endothelin-
2 action via receptor antagonists reduced follicle rupture and oocyte
release (Bridges et al., 2010; Palanisamy et al., 2006). This implies
that endothelin-2 acts by contracting the smoothmuscle layer around
the follicle, resulting in follicular rupture (Ko et al., 2006). Another,
alternative mode of endothelin-2 action in ovulation was suggested,
according to which, endothelin-2 mediates the induction of cGMP-
dependent protein kinase II, a possible downstream target during
the ﬁnal stages of follicular wall breakdown (Palanisamy et al.,
2006). In addition to its effects on follicular rupture, elevated
endothelin-2 levels in the early corpus luteum may facilitate its
formation by promoting angiogenesis, cell proliferation, and differen-
tiation (Klipper et al., 2010). Therefore, decreased production ofendothelin-2 in women with PCOS might interfere with follicular
rupture, the ovulatory process, and corpus luteum formation. In fact,
scanning the ovaries of women with PCOS reveals multiple small,
non-ruptured follicles (Chavez-Ross et al., 1997).
In accordance with ﬁndings reported previously, all endothelin
pathway constituents in human GLCs were expressed in our samples,
including ECE-1, the rate-limiting enzyme in producing active
endothelins (Yoshioka et al., 1998), thus indicating that the ovary is a
source of endothelins. Endothelin peptide levels were not determined
in this study because the available antibodies used in ELISA or other as-
says do not distinguish between endothelin 1 and 2. This is unfortunate
because determining the endothelin peptide levels could substantiate
our ﬁndings and conclusions.
The ample presence of ECE-1 in GLCs observed in this study sug-
gests that GLCs can secrete mature endothelin-1 and endothelin-2
peptides. Both forms of endothelin receptors (ETA and ETB) were
readily expressed in human GLCs of both normally ovulating
women and the PCOS group, indicating that the human ovary is a
suitable site for endothelin action. ETA levels were signiﬁcantly higher
than ETB levels. This is in agreement with a recent study showing that
ETA expression was more abundant in the granulosa cell layer (Choi
et al., 2011). Which receptor type mediates endothelin-2 action in
the ovary remains unclear. Although it was suggested that ETA could
act by inducing smooth muscle constriction around the ovulating fol-
licle (Ko et al., 2006), another study implied that ETB receptors in
granulose cells mediate endothelin-2 induction of target genes during
the ﬁnal stages of follicular wall breakdown (Palanisamy et al., 2006).
Whether ETA in human GLCs mediates granulosa-dependent func-
tions of endothelins is not yet known.
In addition to the ovulatory process, gonadotropins induce and
maintain the steroidogenic function in GLCs. One of the prominent
proteins stimulated by LH/hCG is steroidogenic acute regulatory
protein (StAR), which is responsible for translocating cholesterol
into the mitochondria, leading to the production of their main steroi-
dal product — progesterone (Miller and Strauss, 1999). GLCs derived
from normally ovulating patients treated with controlled ovarian
hyperstimulation exhibited a clear elevation in StAR gene activity in
response to luteotrophic agents (Amsterdam and Selvaraj, 1997;
Christenson and Strauss, 2000). We showed here that StAR mRNA
in GLCs from PCOS patients undergoing controlled ovarian hyper-
stimulation was not different from that found in normally ovulating
women. These ﬁndings might be related to the similar progesterone
concentrations measured in mature follicles from PCOS women and
normally ovulating women undergoing IVF treatment cycles (Teissier
et al., 2000). Only a few studies examined the levels of StAR expression
in fresh GLCs from mature follicles from PCOS patients undergoing
oocyte aspiration, and the results obtained were contradictory. Sander
et al. concluded that women with PCOS exhibited enhanced mRNA
abundance of StAR when compared with controls (Sander et al.,
2011). Paradoxically, they found lower progesterone and estradiol
levels than in healthy follicles. They hypothesized that increased degra-
dation of progesterone to its inactive metabolite is responsible for
this ﬁnding. In another study of PCOS and control patients the mean
levels of StAR mRNA in granulosa cells of a small follicle were similar
(Jakimiuk et al., 2001).
Prolonged culture of the GLCs in gonadotrophin-free medium was
found to re-establish their responsiveness to FSH stimulation and to
enhance the formation of both progesterone and estradiol upon stim-
ulation with either FSH or hCG (Schipper et al., 1993). Using a similar
model, we studied the steroid-synthesizing ability of these cells in
vitro and their responses to luteotrophic stimuli. StAR expression
was elevated in GLCs in response to luteotrophic signals such as
LH/hCG/FSK (data not shown). A clear response was also evident at
the functional level, since these signals increased progesterone produc-
tion by the cells. Although we could restore the steroidogenic response
after 7 days of deprivation, endothelin expression in the GLCs from
708 T. Imbar et al. / Life Sciences 91 (2012) 703–709womenwith PCOS reexposed to luteotrophic signals did not exhibit the
original pattern of expression when puriﬁed immediately after hCG
stimulation in vivo. This may suggest that the regulation of endothelin
expression cannot be only explained by gonadotropins. Several studies
found hypoxia as a critical factor for inducing endothelin-2 in the
periovulatory granulosa cells of bovine and mice (Kim et al., 2009;
Klipper et al., 2010; Na et al., 2008). Altered endothelin expression in
PCOS during the periovulatory stage and CL formation might lead to
the ovulation failure and reduced fertility observed in this syndrome.
The ovarian and the follicular milieu provide other important signals
that might inﬂuence this process and are yet to be discovered. Manipu-
lation of ovarian endothelin levels may prove to be a valuable future
therapeutic target for PCOS patients.
Conclusions
An abnormal endothelin expression pattern in human GLCs from
PCOSmaybe a contributing factor in PCOS pathogenesis; itmay inﬂuence
the ovulation process and corpus luteum formation in an autocrine/
paracrine fashion. Endothelin-1 is known to exert an inhibitory effect
on follicular development and luteinization (Apa et al., 1998; Tedeschi
et al., 1992). Therefore, elevated levels of endothelin-1 in PCOS may
interfere with follicular growth and maturation, resulting in the appear-
ance of excessive small follicles and the lack of corpora lutea typical in
this syndrome. Furthermore, endothelin-2, known to promote follicular
rupture, is lower in PCOS patients. This again may contribute to the
ovulation failure observed in this syndrome.
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